Clinical Trial Update: A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD [Phase 1, Phase 2]

View source ↗

Summary

A pilot safety study evaluating inhaled dry powder mannitol for acute exacerbations of chronic obstructive pulmonary disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Exacerbation of COPD

Drugs mentioned

• Inhaled dry powder mannitol (mannitol)

Snippet

Sponsor: Syntara | Conditions: COPD, Exacerbation | Phase 1, Phase 2 | Status: WITHDRAWN